Get startedLog in
    Picture of Amgen logo

    AMGN — Amgen News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: EMA's PRAC Agrees On DHPC For Tavneos On Reinforced Liver Monitoring Requirements

    Picture of Amgen logoAmgen
    12/06/2026 13:05
    BRIEF-EMA's PRAC Agrees On DHPC For Tavneos On Reinforced Liver Monitoring Requirements
    June 12 (Reuters) - EMA's PRAC:
    • EMA'S PRAC: CONCLUDES EVIDENCE OF POTENTIAL RISK OF NEURODEVELOPMENTAL DISORDERS IN CHILDREN BORN TO MEN TREATED WITH VALPROATE IS INCONSISTENT
    • EMA'S PRAC:  RECOMMENDED CHIKUNGUNYA VACCINE IXCHIQ SHOULD BE RESTRICTED TO INDIVIDUALS WITH HIGH RISK OF BECOMING INFECTED WITH CHIKUNGUNYA VIRUS
    • EMA'S PRAC: AGREES ON DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION FOR TAVNEOS ON REINFORCED LIVER MONITORING REQUIREMENTS

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Amgen

    See all news